In general, and similar to FDA-approved labeling for GLP-1 weight-management medications, you may be considered for a GLP-1 prescription if you: Have a BMI of 30 or higher (obesity), or Have a BMI between 2729.9 (overweight) plus a weight-related health condition Weight-related conditions can include high blood pressure, type 2 diabetes, sleep apnea, high cholesterol, or PCOS (Polycystic Ovary Syndrome), for example
A vial can have 99.5% purity and still contain dramatically less tirzepatide than the label claims
If you use oral contraceptives and start Mounjaro, you should use non-oral contraception or add a barrier method for 4 weeks after initiation and after each dose escalation
Its a partnership between the medication and your diet to achieve your weight loss goals
Current UK guidance from the MHRA and manufacturer clearly states that Wegovy (semaglutide 2.4 mg) should not be used during lactation due to insufficient data on its transfer into breast milk and potential effects on nursing infants